Sunday 18 October 2026
Export APMD’s income statement to Excel — free account
Apnimed, Inc.
APMD
Apnimed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, up 380.1% from fiscal 2024. Insiders bought in the last twelve months.
17.76
0.49
−2.68%
Follow APMD
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+1 more quarter Free account |
1.27 | — | 1.27 | 1.27 |
P/S ratio |
1.02 | — | 1.02 | 1.02 | |
P/FCF ratio |
0.00 | — | 0.00 | 0.00 | |
P/Operating CF |
(6.62) | — | (6.62) | (6.62) | |
P/B ratio |
0.00 | — | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | — | 0.00 | 0.00 | |
EV/Sales |
0.23 | — | 0.23 | 0.23 | |
EV/EBITDA |
1.15 | — | 1.15 | 1.15 | |
EV/Operating CF |
(0.32) | — | (0.32) | (0.32) | |
EV/FCF |
(0.32) | — | (0.32) | (0.32) | |
Quick Ratio |
— | 0.39 | 1.17 | 4.88 | |
Current Ratio |
— | 0.41 | 1.91 | 5.19 | |
Net Debt/EBITDA |
0.00 | 0.00 | (0.12) | 7.97 | |
Debt/Assets |
— | 55.78% | 48.77% | 40.72% | |
Debt/Equity |
— | (0.11) | (0.13) | (0.45) | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
0.25 | — | (0.29) | (0.14) | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
93.33% | — | 9.56% | 81.95% | |
Selling, General and Administrative Expense of Revenue |
31.29% | — | 7.67% | 104.92% | |
Intangible Assets out of Total Assets |
— | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.06% | — | 1.10% | 9.86% | |
Graham Net Nets |
(1.56) | — | (1.56) | (1.56) | |
Graham Number |
0.00 | — | 0.00 | 0.00 | |
Earnings Yield |
78.92% | — | 78.92% | 78.92% | |
Free Cash Flow Yield |
(69.83%) | — | (69.83%) | (69.83%) | |
Revenue per Share |
3.60 | — | 17.69 | 2.52 | |
Operating CF per Share |
(3.65) | — | (4.13) | (3.78) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.65) | — | (4.13) | (3.78) | |
Cash per Share |
0.00 | 0.00 | 9.78 | 36.02 | |
Shareholders Equity per Share |
0.00 | 0.00 | (63.44) | (36.73) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | (63.44) | (36.73) | |
Free Cash Flow |
(17.37) | — | (19.81) | (18.11) | |
Working Capital |
— | (65.82) | 37.17 | 149.19 | |
Net Current Asset Value |
— | (400.60) | (304.98) | (186.86) | |
EV/EBIT |
1.15 | — | 1.15 | 1.15 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Price to Operating Income |
5.15 | — | 5.15 | 5.15 |
Columns are period end dates · fundamentals updated 7 Oct 2026